Alto Ingredients, Inc. (NASDAQ:ALTO ) Q4 2024 Earnings Conference Call March 5, 2025 5:00 PM ET Company Participants Kirsten Chapman - IR, Alliance Advisors IR Bryon McGregor - President and CEO Rob Olander - CFO Conference Call Participants Sameer Joshi - H.C. Wainwright Eric Stine - Craig-Hallum Operator Good evening, and welcome to the Alto Ingredients Fourth Quarter and Year-End 2024 Financial Results Conference Call.
- Implemented Cost Savings Expected to Yield Approximately $8 Million Annually - - Integrated Accretive Acquisition of a Beverage-grade Liquid CO 2 Processor - - Considering Asset Sales, a Merger or Other Strategic Transactions -
PEKIN, Ill., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO) a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, announced it will release its fourth quarter and year-end 2024 financial results after the close of market on Wednesday, March 5, 2025.
Alto Ingredients Could Soon Have The Right Recipe For A Rebound
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375, with method claims pertaining to treatment of major depressive disorder (MDD) in patients with inadequate response to an antidepressant. The method includes treatment with ALTO-300.
- Secures improved, long-term CO2 sales contract,creating immediate bottom-line accretion and future financial upside -
- Plant to Operate as a Terminal - PEKIN, Ill., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, has announced that it will cold idle its Magic Valley, Idaho facility on December 31, 2024, yet continue to provide terminal services at the plant.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo. The favorable safety and tolerabili.
PEKIN, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuel and essential ingredients, provided updates on its Magic Valley facility in Idaho where it has installed Harvesting Technology's patented system to capture its high protein and corn oil products.
Alto Ingredients (ALTO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.